Correlation of enzyme-inducing anticonvulsant use with outcome of patients with glioblastoma.

ABSTRACT:

Background

Clinical trials involving patients with glioblastoma (GBM) distinguish cohorts who are treated with enzyme-inducing anticonvulsants (EIAC). Such anticonvulsants induce hepatic P450 microsomal enzymes, which accelerate the metabolism of certain chemotherapy and molecular targeted agents. However, the resultant effect of such induction on patient outcome has received limited study.

Methods

We performed a correlative analysis of baseline EIAC use with outcome, using a cross-sectional database of 620 patients with newly diagnosed GBM treated prospectively on North Central Cancer Treatment Group trials.

Results

At registration, 72% were receiving treatment with EIAC; 2% were receiving non-EIACs, and the 26% were not receiving anticonvulsants (26%). Surprisingly,

SUBMITTER: Jaeckle KA 

PROVIDER: S-EPMC2764724 | biostudies-literature | 2009 Oct

REPOSITORIES: biostudies-literature